UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2204-11
Program Prior Authorization/Medical Necessity
Medication *Ustekinumab: **Otulfi® (ustekinumab-aauz), **Pyzchiva®
(ustekinumab-ttwe), **Selarsdi™ (ustekinumab-aekn), **Stelara®
(ustekinumab), Steqeyma® (ustekinumab-stba), **Ustekinumab-ttwe,
Wezlana™ (ustekinumab-auub), and Yesintek™ (ustekinumab-kfce)
*This program applies to the subcutaneous formulation of ustekinumab.
**Otulfi (ustekinumab-aauz), Pyzchiva (ustekinumab-ttwe), Selarsdi
(ustekinumab-aekn), Stelara® (ustekinumab), and Ustekinumab-ttwe
are excluded from coverage for the majority of our benefits.
P&T Approval Date 5/2020, 5/2021, 6/2021, 12/2021, 9/2022, 3/2023, 7/2023, 10/2024,
3/2025, 5/2025
Effective Date 9/15/2025
1. Background:
Ustekinumab is a human interleukin-12 and -23 antagonist indicated for the treatment of adult
and pediatric patients 6 years of age or older with active psoriatic arthritis and for moderate to
severe plaque psoriasis who are candidates for phototherapy or systemic therapy. It is also
indicated in adult patients with moderately to severely active Crohn’s disease and for
moderately to severely active ulcerative colitis.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Ustekinumab 45 mg/0.5 mL will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) One of the following:
(a) All of the following:
i. Greater than or equal to 3% body surface area involvement,
palmoplantar, facial, genital involvement, or severe scalp psoriasis
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
ii. History of failure to one of the following topical therapies, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trial):
a. Corticosteroids (e.g., betamethasone, clobetasol, desonide)
b. Vitamin D analogs (e.g., calcitriol, calcipotriene)
c. Tazarotene
d. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
e. Anthralin
f. Coal tar
-AND-
iii. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of plaque psoriasis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla
(apremilast), Skyrizi (risankizumab), Tremfya (guselkumab)].
-OR-
(c) Both of the following:
i. Patient is currently on the requested ustekinumab product therapy as
documented by claims history or submission of medical records
(Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a manufacturer
sponsored program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of the requested ustekinumab product *
-AND-
(3) Patient is not receiving the requested ustekinumab product in combination
with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
© 2025 UnitedHealthcare Services, Inc.
2
-AND-
(4) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt of
a manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a manufacturersponsored program shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
b. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) Patient’s weight is > 100 kg (220 lbs.)
-AND-
(3) One of the following:
(a) All of the following:
i. Greater than or equal to 3% body surface area involvement,
palmoplantar, facial, genital involvement, or severe scalp psoriasis
-AND-
ii. History of failure to one of the following topical therapies, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trial):
a. Corticosteroids (e.g., betamethasone, clobetasol, desonide)
b. Vitamin D analogs (e.g., calcitriol, calcipotriene)
c. Tazarotene
d. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
e. Anthralin
f. Coal tar
-AND-
iii. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
© 2025 UnitedHealthcare Services, Inc.
3
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of plaque psoriasis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla
(apremilast), Skyrizi (risankizumab), Tremfya (guselkumab)].
-OR-
(c) Both of the following:
i. Patient is currently on the requested ustekinumab product therapy as
documented by claims history or submission of medical records
(Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a manufacturer
sponsored program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of the requested ustekinumab product *
-AND-
(4) Patient is not receiving the requested ustekinumab product in combination
with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
-AND-
(5) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt of
a manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a manufacturersponsored program shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Ustekinumab 45 mg/0.5 mL or 90 mg/mL will be approved based on all of the
following criteria:
(1) Documentation of positive clinical response to the requested ustekinumab
therapy
© 2025 UnitedHealthcare Services, Inc.
4
-AND-
(2) Patient is not receiving the requested ustekinumab product in combination
with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Ustekinumab 45 mg/0.5 mL will be approved based on all of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) One of the following:
(a) History of failure to a 3 month trial of methotrexate at maximally indicated
dose, unless contraindicated or clinically significant adverse effects are
experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of psoriatic arthritis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi
(golimumab), Tremfya (guselkumab) Xeljanz (tofacitinib), Otezla
(apremilast), Rinvoq (upadacitinib)].
-OR-
(c) Both of the following:
i. Patient is currently on the requested ustekinumab product therapy as
documented by claims history or submission of medical records
(Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a manufacturer
© 2025 UnitedHealthcare Services, Inc.
5
sponsored program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of the requested ustekinumab product *
-AND-
(3) Patient is not receiving the requested ustekinumab product in combination
with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Rheumatologist
(b) Dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt of
a manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a manufacturersponsored program shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
b. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) Patient’s weight is > 100 kg (220 lbs.)
-AND-
(3) One of the following:
(a) History of failure to a 3 month trial of methotrexate at maximally indicated
dose, unless contraindicated or clinically significant adverse effects are
experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of psoriatic arthritis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi
© 2025 UnitedHealthcare Services, Inc.
6
(golimumab), Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib),
Otezla (apremilast), Rinvoq (upadacitinib)].
-OR-
(c) Both of the following:
i. Patient is currently on the requested ustekinumab product therapy as
documented by claims history or submission of medical records
(Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a manufacturer
sponsored program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of the requested ustekinumab product
-AND-
(4) Patient is not receiving the requested ustekinumab product in combination
with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
-AND-
(5) Prescribed by or in consultation with one of the following:
(a) Rheumatologist
(b) Dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt of
a manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a manufacturersponsored program shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Ustekinumab 45 mg/0.5 mL or 90 mg/mL will be approved based on all of the
following criteria:
(1) Documentation of positive clinical response to the requested ustekinumab
therapy
© 2025 UnitedHealthcare Services, Inc.
7
-AND-
(2) Patient is not receiving the requested ustekinumab product in combination
with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
* Patients requesting initial authorization who were established on therapy via the receipt of
a manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a manufacturer sponsored program shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
C. Crohn’s Disease (CD)
1. Initial Authorization for Maintenance Dosing
a. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) One of the following:
(a) Patient has been established on therapy with the requested ustekinumab
product under an active UnitedHealthcare medical benefit prior
authorization for treatment of moderately to severely active Crohn’s disease
-OR-
(b) Both of the following:
i. Patient is currently on the requested ustekinumab product therapy for
moderately to severely active Crohn’s disease as documented by claims
history or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a
manufacturersponsored program (e.g., sample card which can be
redeemed at a pharmacy for a free supply of medication) as a means to
establish as a current user of the requested ustekinumab product *
-AND-
© 2025 UnitedHealthcare Services, Inc.
8
(3) Patient is not receiving the requested ustekinumab product in combination with
another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi
(risankizumab)]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the receipt of
a manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a manufacturer sponsored program shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Ustekinumab will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to the requested ustekinumab
therapy
-AND-
(2) Patient is not receiving the requested ustekinumab product in combination with
another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi
(risankizumab)]
Authorization will be issued for 12 months.
D. Ulcerative Colitis
1. Initial Authorization
a. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) One of the following:
(a) Patient has been established on therapy with the requested ustekinumab
product under an active UnitedHealthcare medical benefit prior
© 2025 UnitedHealthcare Services, Inc.
9
authorization for treatment of moderately to severely active ulcerative
colitis
-OR-
(b) Both of the following:
i. Patient is currently on the requested ustekinumab product therapy for
moderately to severely active ulcerative colitis as documented by claims
history or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a manufacturer
sponsored program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of the requested ustekinumab product *
-AND-
(3) Patient is not receiving the requested ustekinumab product in combination
with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi
(risankizumab)]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the receipt of
a manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a manufacturersponsored program shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Ustekinumab will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to the requested ustekinumab
therapy
-AND-
(2) Patient is not receiving the requested ustekinumab product in combination
with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia
© 2025 UnitedHealthcare Services, Inc.
10
(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi
(risankizumab)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
**Otulfi (ustekinumab-aauz), Pyzchiva (ustekinumab-ttwe), Selarsdi (ustekinumab-aekn), Stelara
(ustekinumab), and Ustekinumab-ttwe are excluded from coverage for the majority of our benefits.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
• The intravenous infusion is typically covered under the medical benefit. Please refer to the
UnitedHealthcare Drug Policy for Ustekinumab.
4. Reference:
1. Stelara [package insert]. Horsham, PA: Janssen Biotech Inc.; March 2024.
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of
psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an
emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis
with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
7. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for
the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment
of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J
Am Acad Dermatol. 2011 Jul;65(1):137-74.
8. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the
management of moderate to severe ulcerative colitis. Gastroenterology. 2020; 158(5):1450-61.
9. Lichtenstein GR, Loftus EV, Isaacs KL, et al ACG clinical guideline: management of Crohn’s
disease in adults. Am J Gastroenterol. 2018; 113:481-517.
© 2025 UnitedHealthcare Services, Inc.
11
10. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management
and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.
11. Steqeyma [package insert]. Jersey City, NJ: Celltrion USA, Inc.; December 2024.
12. Yesintek [package insert]. Cambridge, MA: Biocon Biologics Inc.; November 2024.
13. Selarsdi [package insert], Boston, MA: argenx US, Inc.; June 2025.
14. Otulfi [package insert], Lake Zurich, IL: Fresenius Kabi USA, LLC; September 2024.
15. Pyzchiva [package insert], Princeton, NJ: Sandoz Inc.; December 2024.
16. Wezlana [package insert]. Thousand Oaks, CA: Amgen Inc. for Nuvaila; January 2025.
Program Prior Authorization/Medical Necessity - Ustekinumab: **Otulfi
(ustekinumab-aauz), **Pyzchiva (ustekinumab-ttwe), **Selarsdi
(ustekinumab-aekn), **Stelara (ustekinumab), Steqeyma (ustekinumab-
stba), **Ustekinumab-ttwe, Wezlana (ustekinumab-auub), and Yesintek
(ustekinumab-kfce)
Change Control
5/2020 New program
5/2021 Annual review. Removed preceding month requirement from failure
criteria. Removed prescriber requirement from reauthorization criteria.
Updated UC coverage criteria to align with other Med Nec programs.
Removed drug documentation where only one drug is required.
References and background updated.
6/2021 Added coverage criteria for patients previously treated with a biologic
DMARD. Added clarification that submission of medical records is
required documenting previous or current therapy with a biologic
DMARD in order to bypass step through non-biologic therapies if claim
history not available.
12/2021 Updated conventional DMARD bypass language for psoriasis, psoriatic
arthritis and ulcerative colitis with no change to clinical intent. Updated
initial authorization duration to 12 months for ulcerative colitis.
Updated CT/KY footnote.
9/2022 Updated background to include patients 6 years and older with active
psoriatic arthritis. Added Mississippi to state mandate footnote.
Updated reference.
3/2023 Removed step through conventional therapy for CD and UC. Replaced
with verbiage that patient has been established on therapy with Stelara
under an active UnitedHealthcare prior authorization. Added Rinvoq as
a JAKI example. Changed Humira examples to adalimumab. Updated
reference.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Annual review. Updated criteria for Crohn’s disease and ulcerative
colitis for establishment of therapy on the medical benefit without
change to clinical coverage intent. Updated reference and state mandate
footnote.
3/2025 Added Steqeyma and Yesintek to all coverage criteria in parity with
Stelara. Updated background and reference.
© 2025 UnitedHealthcare Services, Inc.
12
5/2025 Renamed program to Ustekinumab. Added Otulfi (ustekinumab-aauz),
Pyzchiva (ustekinumab-ttwe), Selarsdi (ustekinumab-aekn),
Ustekinumab-ttwe, and Wezlana (ustekinumab-auub) to the program.
Added notation stating some products are excluded from coverage for
the majority of our benefits. Updated Stelara, Steqeyma, or Yesintek to
Ustekinumab throughout the program. Updated references.
9/5/2025 Administrative change to add Wezlana into coverage.
© 2025 UnitedHealthcare Services, Inc.
13